By staff writers

July 16, 2013 -- Radiopharmaceutical developer Navidea Biopharmaceuticals said that an Australian clinical study plans to switch the radiopharmaceutical it is using to Navidea's NAV4694 beta-amyloid imaging candidate.

Instead of using carbon-11-labeled Pittsburgh Compound B (PiB) for its research initiative in Alzheimer's disease and mild cognitive impairment, the Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Aging (AIBL) will now utilize Navidea's F-18-labeled beta-amyloid imaging agent, Navidea said.

In other Navidea news, the company reported that Dr. Jess Emery Jones has resigned as a member of the firm's board of directors for personal reasons, effective July 9. Jones has served on the board since April 2011, and the company said it expects to undertake a process in the near future to evaluate the board's composition.

Copyright © 2013

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking